Advisory Board

Tesheia Johnson, MBA, MHS

Chief Operating Officer, Yale Center for Clinical Investigation; Associate Director, Clinical Research, Yale School of Medicine

Tesheia Johnson, MBA, MHS, is currently the Chief Operating Officer for the Yale Center for Clinical Investigation and the Associate Director for Clinical Research for the Yale School of Medicine. Prior to assuming this position, she was the Assistant Dean for Clinical Research at the University of Vermont College of Medicine. In this role, Ms. Johnson provided leadership and direction in the area of clinical trial research, which includes strategic planning and research development. She previously held positions as Director of Clinical Trials at the University of Wisconsin-Madison Medical School, Administrator for Clinical Research for the Departments of Surgery and Pediatrics at Yale School of Medicine and Assistant Director for Marketing for BIOS, a small biotechnology firm.

Ms. Johnson holds a Master of Business Administration and a Master of Health Sciences. Ms. Johnson’s career has been focused on the development of clinical research programs and support infrastructure. She has also served as a consultant for several academic centers interested in establishing clinical research programs and has served as a grant reviewer for an NIH study session. She is nationally recognized for her expertise in design and setup of clinical research programs and for her ability to establish strong partnerships with industry. She has been the invited speaker for many national conferences on topics such as: developing and funding for central support for clinical research, staffing models for clinical and translational research, training programs for research professionals, clinical research regulation, contracting and budget negotiation. Ms. Johnson has served as the co-Chair for the National CTSA Consortium Management Group (selected to be one of only 5 across the consortium), Clinical Research Management, Administration, and Regulatory Key Function Committees. She also sits on the external scientific advisory boards for the CTSAs at Mayo Clinic, NYU and University of Florida.

Marc Drezner, MD

Director, UW ICTR; Senior Associate Dean for Clinical and Translational Research in the School of Medicine and Public Health

Director of the UW ICTR is Marc Drezner, MD, who has ultimate responsibility for the academic activities of the Institute, as well as management of the resources and supervision of personnel. Dr. Drezner, Senior Associate Dean for Clinical and Translational Research in the School of Medicine and Public Health, is an active and experienced translational and clinical investigator. He is internationally known for his scientific work in bone and mineral metabolism and has made seminal contributions to the knowledge regarding several genetic diseases. He is also section head for endocrinology, diabetes and metabolism.

Dr. Drezner has served as Professor of Medicine and Head, Endocrinology, Diabetes and Metabolism Section; Senior Vice Chairman of Research, Department of Medicine; Program Director of the GCRC; and most recently Associate Dean of Clinical and Translational Research in the School of Medicine and Public Health. He also serves on the National CTSA Clinical Research Management & Community Engagement Key Function Committees. In the academic community, he has been Editor-in-Chief of the Journal of the American Society for Bone and Mineral Research and Secretary-Treasurer of the American Society of Bone and Mineral Research. Marc Drezner, MD, received his medical degree from the University of Pittsburgh in 1970.

Alastair J.J. Wood, MD

Partner and Managing Director, Symphony Capital LLC; Chairman, Symphony’s Clinical Advisory Council; Director, Symphony Evolution, Inc. and Symphony Neuro Development Company

Dr. Alastair J. J. Wood serves as a Partner and Managing Director at Symphony Capital LLC. Dr. Wood joined Symphony Capital LLC in September 2006, after completing more than 30 years at Vanderbilt University School of Medicine. Dr. Wood has worked with the firm since its inception as Chairman of Symphony’s Clinical Advisory Council. He serves as a Director at Symphony Evolution, Inc. and Symphony Neuro Development Company. He has been Director of Oxigene Inc. since October 22, 2008. Until 2006, Dr. Wood has been a Member of and Chaired National Institutes of Health study sections and served on the Editorial Boards of four major journals, including the New England Journal of Medicine. Between 1992 and 2004, Dr. Wood was a Drug Therapy Editor of The New England Journal of Medicine. He serves as a Professor of Medicine and Professor of Pharmacology at Weill Cornell Medical School. Dr. Wood was at Vanderbilt University School of Medicine, most recently as an Associate Dean of External Affairs. He was also an Attending Physician and Tenured Professor of Medicine and Pharmacology at Vanderbilt. During the past 30 years, he has written or co-authored more than 300 scientific papers and won numerous honors, including election to the Institute of Medicine of the National Academy of Sciences. Dr. Wood holds an M.D. from the University of St. Andrews.

Beverly R. Ginsburg-Cooper, MBA

Senior Director, Huron Consulting Group

Beverly has more than 20 years of executive management and consulting experience, specializing in helping cancer centers and academic institutions with strategic planning, operations improvement and compliance management. Prior to joining Huron Consulting Group, Beverly held positions as Senior Vice President for Research at Dana-Farber Cancer Institute, Associate Director for Administration at Dana-Farber/Harvard Cancer Center, Executive Director of the Abramson Cancer Center, President of Medical Partnerships, Inc., Vice President of Pennsylvania Hospital, and Chief Operating Officer of a community hospital. She received her bachelor’s degree in education from Adelphi University and her MBA from the Wharton School of the University of Pennsylvania. Currently, she is a member of the external advisory boards of several comprehensive cancer centers. She was formerly president of the Cancer Center Administrators Forum.